Fisher & Paykel Healthcare Corporation Limited today announced strong financial results for the 2022 financial year, with operating revenue of $1.68 billion, a 15% decline from the previous financial year, or a 14% decline in constant currency.
Total operating revenue for the 2022 financial year was down 15% or 14% in constant currency.
Net profit after tax was $376.9 million, a 28% decline from the previous financial year, or a 30% decline in constant currency.
During the 2022 financial year, the company invested $154 million into research and development, resulting in the launch of several new products, including Optiflow Switch™ and Optiflow Trace™ nasal high flow interfaces, as well as the revolutionary new Airvo™ 3 device.
The company also announced a final dividend of 22.5 cents per share, bringing the total dividend for the year to 39.5 cents per share, an increase of 4%.
To acknowledge the people of Fisher & Paykel Healthcare, directors also approved a profit-sharing payment totalling $19 million for the 2022 financial year.
Management has not provided quantitative revenue or earnings guidance for the 2023 financial year due to the ongoing uncertainties in the global markets.
See more
